October 20, 2021

Medical Trend

Medical News and Medical Resources

Australia will purchase 300000 doses of Merck oral COVID-19 drug

Australia will purchase 300000 doses of Merck oral COVID-19 drug

Australia will purchase 300000 doses of Merck oral COVID-19 drug



 

Australia will purchase 300000 doses of Merck oral COVID-19 drug. Molnupiraviris the first experimental oral drug against COVID-19 disease.

Australian Prime Minister Morrison announced on Tuesday (5th) that Australia will purchase 300,000 doses of an experimental oral COVID-19 drug from the American pharmaceutical company Merck & Co.

 

Reuters reported that the drug called Molnupiravir is the first oral anti-COVID-19  drug. Experts said that if Molnupiravir is approved by the drug regulatory authority, it will be expected to halve deaths and hospitalizations from COVID-19 disease.

 

Morrison said in an interview with Australian News Network Nine on Tuesday that 10 tablets of Molnupiravir are a course of treatment. Every adult patient with COVID-19 disease must take Molnupiravir for five consecutive days, two pills each time.

Morrison said: “Molnupiravir will allow us to coexist with the coronavirus.”

 

He also said that once approved by the Australian Drug Administration, Australia should receive 300,000 copies of Molnupiravir early next year.

 

Merck expects to produce 10 million courses of Molnupiravir by the end of this year.

The clinical trial of Molnupiravir was conducted in the Philippines. South Korea, Thailand, Taiwan and Malaysia all indicated that they are negotiating with Merck on the purchase of this oral drug.

 

Molnupiravir From Wikipedia, the free encyclopedia

Molnupiravir (development codes MK-4482 and EIDD-2801) is an experimental antiviral drug which is orally active and was developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication.[1][2]

The drug was developed at Emory University by the university’s drug innovation company, Drug Innovation Ventures at Emory (DRIVE). It was then acquired by Miami-based company Ridgeback Biotherapeutics, who later partnered with Merck & Co. to develop the drug further.[3]

 

(source:internet, reference only)


Disclaimer of medicaltrend.org